GMED in the 13F filings
Globus Medical Inc · CUSIP 379577208
- Quarter end
- 30 Sep 2023
- the date the book describes
- Filed
- 21 Nov 2023
- latest of these filings; the earliest 7 Nov 2023
- Managers listing it
- 17
- at least, of 95 tracked, among listed positions
- Comparable managers
- 93
- filed both Q2 2023 and Q3 2023; 14 listed it in both
- Shares listed
- 17,735,981
- combined, among listed positions
- Reported value
- $881m
- combined, at the quarter end
Managers listing GMED in Q3 2023
Share of 13F value is the position’s reported value over everything the manager reported that quarter. The share change is against Q2 2023, and only where both filings list the position. A rise in value with no rise in shares is the price, not buying.
17 of 17 holders
Largest increases and reductions, by shares
Q2 2023 to Q3 2023, among managers that listed it in both quarters or opened it.
Increases
- Janus Henderson Group Ltdexisting position · 8,274,610 shares now+1,183,756
- Two Sigma Investments LPexisting position · 1,429,335 shares now+642,140
- Marshall Wace LLPexisting position · 1,386,078 shares now+637,959
- Capital World Investorsnew position · 574,500 shares now+574,500
- Two Sigma Advisers LPexisting position · 1,344,500 shares now+468,000
Reductions
- Holocene Advisors LPexisting position · 83,556 shares now-47,901
- Voloridge Investment Management LLCexisting position · 258,904 shares now-32,875
- Element Capital Management LLCexisting position · 58,888 shares now-5,297
New positions and exits
At least these many: a manager is shown exiting only where its own filing shows the position gone.
New (1)
Exited (3)
- Point72 Asset Management LPwas $56m
- Davidson Kempner Capital Management LPwas $28m
- Caxton Associates LLPwas $1.1m
Ownership over time
Every quarter on file. A quarter-end value moves with the price as well as with the shares held; buyers and sellers count comparable managers, by shares.
12 in Q3 2024 to 10 in Q2 2026
Tracked managers listing it, at least.
the quarter shown share split complete books; unmarked quarters rest on listed positionsClick a quarter to open it.
| Quarter | Holders | Reported value | Buyers | Sellers |
|---|---|---|---|---|
| Q2 2013 | 2 | $32m | n.a. | n.a. |
| Q3 2013 | 2 | $131m | n.a. | n.a. |
| Q4 2013 | 2 | $154m | n.a. | n.a. |
| Q1 2014 | 2 | $188m | n.a. | n.a. |
| Q2 2014 | 6 | $144m | n.a. | n.a. |
| Q3 2014 | 4 | $134m | n.a. | n.a. |
| Q4 2014 | 4 | $136m | n.a. | n.a. |
| Q1 2015 | 3 | $154m | n.a. | n.a. |
| Q2 2015 | 4 | $195m | n.a. | n.a. |
| Q3 2015 | 5 | $155m | n.a. | n.a. |
| Q4 2015 | 2 | $215m | n.a. | n.a. |
| Q1 2016 | 4 | $194m | n.a. | n.a. |
| Q2 2016 | 3 | $200m | n.a. | n.a. |
| Q3 2016 | 3 | $215m | n.a. | n.a. |
| Q4 2016 | 4 | $232m | n.a. | n.a. |
| Q1 2017 | 4 | $233m | n.a. | n.a. |
| Q2 2017 | 2 | $266m | n.a. | n.a. |
| Q3 2017 | 5 | $341m | n.a. | n.a. |
| Q4 2017 | 5 | $482m | n.a. | n.a. |
| Q1 2018 | 7 | $588m | n.a. | n.a. |
| Q2 2018 | 7 | $513m | n.a. | n.a. |
| Q3 2018 | 13 | $674m | n.a. | n.a. |
| Q4 2018 | 13 | $570m | n.a. | n.a. |
| Q1 2019 | 5 | $619m | n.a. | n.a. |
| Q2 2019 | 5 | $589m | n.a. | n.a. |
| Q3 2019 | 6 | $733m | n.a. | n.a. |
| Q4 2019 | 12 | $832m | n.a. | n.a. |
| Q1 2020 | 7 | $597m | n.a. | n.a. |
| Q2 2020 | 6 | $610m | n.a. | n.a. |
| Q3 2020 | 8 | $639m | n.a. | n.a. |
| Q4 2020 | 6 | $855m | n.a. | n.a. |
| Q1 2021 | 7 | $779m | n.a. | n.a. |
| Q2 2021 | 10 | $997m | n.a. | n.a. |
| Q3 2021 | 9 | $871m | n.a. | n.a. |
| Q4 2021 | 10 | $912m | n.a. | n.a. |
| Q1 2022 | 10 | $934m | n.a. | n.a. |
| Q2 2022 | 7 | $684m | n.a. | n.a. |
| Q3 2022 | 6 | $781m | n.a. | n.a. |
| Q4 2022 | 6 | $840m | n.a. | n.a. |
| Q1 2023 | 15 | $720m | n.a. | n.a. |
| Q2 2023 | 21 | $946m | n.a. | n.a. |
| Q3 2023 | 17 | $881m | n.a. | n.a. |
| Q4 2023 | 12 | $912m | 5 | 7 |
| Q1 2024 | 8 | $772m | 2 | 5 |
| Q2 2024 | 13 | $1.0bn | 6 | 6 |
| Q3 2024 | 12 | $868m | 5 | 6 |
| Q4 2024 | 14 | $1.4bn | 5 | 6 |
| Q1 2025 | 13 | $951m | 9 | 4 |
| Q2 2025 | 12 | $897m | 10 | 1 |
| Q3 2025 | 11 | $765m | 6 | 4 |
| Q4 2025 | 13 | $1.6bn | 12 | 20 |
| Q1 2026 | 14 | $1.6bn | 19 | 15 |
| Q2 2026 | 10 | $1.1bn | 14 | 18 |
Compare with…
Holders over time, buyers and sellers, and the managers holding both, side by side for up to four stocks.
GMED and LLY →GMED and JNJ →GMED and VRTX →Choose a stock to compare with GMED →
How much of the picture this is
A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. It shows no shorts, cash, bonds or performance, and it is never today’s portfolio. Large books are listed to their largest positions, so a manager missing from this table may still hold a small position below that line. These are 95 tracked managers, not the institutional market.
Which funds own GMED, latest filings →Back to the 13F Explorer →